Elutia regains compliance with Nasdaq listing requirements

Elutia Inc. announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and majority independent board requirement. As a result, the Company now satisfies all applicable requirements for continued listing with Nasdaq, and the Company’s Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”

“We are pleased to have received confirmation from Nasdaq of our compliance with their listing requirements,” said Kevin Rakin, Chairman of Elutia. “With the divestiture of our orthopedics business and successful capital raise, 2023 was a transformative year for Elutia. Randy Mills, our CEO, and the leadership team are now fully focused on the commercial launch of our pioneering drug-eluting biomatrix, CanGarooRM®, and we look forward to a favorable FDA decision in the first half of this year.”
MB Bureau